−3.1324USD
−100.89 MUSD
15.30 MUSD
30.65 M
About DermTech, Inc.
Sector
Industry
CEO
Bret Christensen
Website
Headquarters
San Diego
Employees (FY)
208
Founded
1995
ISIN
US24984K1051
FIGI
BBG00H19F184
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of DMTK is 0.6440 USD — it has increased by 8.97% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange DermTech, Inc. stocks are traded under the ticker DMTK.
DermTech, Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
DMTK stock is 16.50% volatile and has beta coefficient of 2.80. Check out the list of the most volatile stocks — is DermTech, Inc. there?
One year price forecast for DermTech, Inc. has a max estimate of 4.0000 USD and a min estimate of 0.6300 USD.
DMTK earnings for the last quarter are −0.57 USD per share, whereas the estimation was −0.76 USD resulting in a 25.38% surprise. The estimated earnings for the next quarter are −0.57 USD per share. See more details about DermTech, Inc. earnings.
DermTech, Inc. revenue for the last quarter amounts to 3.92 M USD despite the estimated figure of 3.90 M USD. In the next quarter revenue is expected to reach 4.04 M USD.
Yes, you can track DermTech, Inc. financials in yearly and quarterly reports right on TradingView.
DMTK stock has fallen by 0.92% compared to the previous week, the month change is a 9.55% fall, over the last year DermTech, Inc. has showed a 85.23% decrease.
DMTK net income for the last quarter is −19.09 M USD, while the quarter before that showed −19.16 M USD of net income which accounts for 0.38% change. Track more DermTech, Inc. financial stats to get the full picture.
Today DermTech, Inc. has the market capitalization of 20.46 M, it has decreased by 3.84% over the last week.
No, DMTK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DMTK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DermTech, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 208.00 employees. See our rating of the largest employees — is DermTech, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DermTech, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DermTech, Inc. stock shows the sell signal. See more of DermTech, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on DermTech, Inc. future price: according to them, DMTK price has a max estimate of 4.00 USD and a min estimate of 0.63 USD. Read a more detailed DermTech, Inc. forecast: see what analysts think of DermTech, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DermTech, Inc. EBITDA is −97.89 M USD, and current EBITDA margin is −639.99%. See more stats in DermTech, Inc. financial statements.